Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822780 | 0.87 | ALDH1A1 (0.36) | DPP8DPP9MEN1KMT2ACYP19A1 | |
| SCHEMBL2208058 | 0.86 | MEN1 (0.36) | DPP8DPP9MEN1KMT2AMAPK1 | |
| SCHEMBL15182745 | 0.84 | DPP4 (0.32) | DPP4 | |
| SCHEMBL6560570 | 0.83 | DPP4 (0.37) | MEN1KMT2ADPP4NAAAALDH1A1 | |
| SCHEMBL23974125 | 0.81 | DPP8 (0.32) | DPP8DPP9DPP4 | |
| SCHEMBL1733328 | 0.81 | CYP17A1 (0.35) | DPP8DPP9MEN1KMT2AMAPK1 | |
| SCHEMBL12432875 | 0.80 | TSHR (0.40) | MEN1KMT2ANAAAALDH1A1 | |
| SCHEMBL776350 | 0.80 | DPP8 (0.30) | DPP8DPP9 | |
| SCHEMBL19862666 | 0.79 | CYP17A1 (0.30) | DPP8DPP9CYP17A1CYP19A1 | |
| SCHEMBL12153604 | 0.79 | GAA (0.33) | DPP8DPP9MEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156854-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7528279-B2 | Adamantane derivatives and process for producing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20070129532-A1 | Adamantane derivatives and process for producing the same | IDEMITSU KOSAN CO., LTD (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1712542-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156854-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ADH1A, ADH5, TAS1R2 | DPP8 2184/4885DPP9 1134/4885MEN1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.